Molecure completes successful Secondary Public Offering (SPO) of approximately PLN 50 million (USD 12 million) with proceeds to be used to fund and build a first in class, sustainable pipeline of breakthrough therapies

By / 21/07/2023

Molecure completes successful Secondary Public Offering (SPO) of approximately PLN50 million (USD12 million) with proceeds to be used to fund and build a first in class, sustainable pipeline of break through therapies